What was Celltrion Pharm's operating profit in Q3 2026?

KRW 23.9 billion on a separate basis. The comparison figure was KRW 16.1 billion in Q3 2025 (up 48.4%).

What was Celltrion Pharm's revenue in Q3 2026?

KRW 161.9 billion on a separate basis. The comparison figure was KRW 138.2 billion in Q3 2025 (up 17.2%).

What was Celltrion Pharm's net income in Q3 2026?

KRW 17.7 billion on a separate basis. The comparison figure was KRW 11.5 billion in Q3 2025 (up 54.2%).

What should readers check next on Celltrion Pharm?

Check whether the final earnings filing changes the preliminary figures. Check the audit report for any changes after the external audit. Check the quarterly report for how consolidated results differ from separate results.

Which filings is this based on?

영업(잠정)실적(공정공시) (DART, 2026-11-09).

Is this a buy recommendation?

No. This is for information only and is not investment advice. You are responsible for your own investment decisions and their results.

Celltrion Pharm Earnings: Operating profit rose 48.4% from a year earlier

2 / 5

What changed

Operating profit

KRW 23.9 billion

Q3 2026, Separate, up 48.4%

Revenue

KRW 161.9 billion

Q3 2026, Separate, up 17.2%

Net income

KRW 17.7 billion

Q3 2026, Separate, up 54.2%

Revenue for Q3 2026 was KRW 161.9 billion, up 17.2% from a year earlier.
Operating profit was KRW 23.9 billion and net income was KRW 17.7 billion, with operating profit up 48.4% from a year earlier.
Net income rose 54.2% from a year earlier.

3 / 5

Context

Q3 2025KRW 16.1 billion

Q3 2026KRW 23.9 billion

Operating profit was KRW 16.1 billion in Q3 2025 and KRW 19.3 billion in Q2 2026.
For 9M 2026, revenue was KRW 447.3 billion and operating profit was KRW 56.1 billion, both on a separate basis.

4 / 5

What to check next

ConditionCheck whether the final earnings filing changes the preliminary figures.
UncertaintyCheck the audit report for any changes after the external audit.
ConditionCheck the quarterly report for how consolidated results differ from separate results.

5 / 5

Sources and wrap-up

These are preliminary figures on a separate basis, and that should frame how they are read.

Sources

영업(잠정)실적(공정공시)DART, 2026-11-09

Facts used in the cards

Values and passages are copied from the original filings.

Revenue: KRW 161.9 billion: Q3 2026, Separate, DART; 매출액 당해실적 161,874 153,291 5.60 - 138,175 17.15 -
Revenue (Q3 2025): KRW 138.2 billion: Q3 2025, Separate, DART; 매출액 당해실적 161,874 153,291 5.60 - 138,175 17.15 -
Operating profit: KRW 23.9 billion: Q3 2026, Separate, DART; 영업이익 당해실적 23,901 19,306 23.80 - 16,108 48.38 -
Operating profit (Q3 2025): KRW 16.1 billion: Q3 2025, Separate, DART; 영업이익 당해실적 23,901 19,306 23.80 - 16,108 48.38 -
Net income: KRW 17.7 billion: Q3 2026, Separate, DART; 당기순이익 당해실적 17,671 13,721 28.79 - 11,459 54.21 -
Net income (Q3 2025): KRW 11.5 billion: Q3 2025, Separate, DART; 당기순이익 당해실적 17,671 13,721 28.79 - 11,459 54.21 -
Operating profit (Q2 2026): KRW 19.3 billion: Q2 2026, Separate, DART; 영업이익 당해실적 23,901 19,306 23.80 - 16,108 48.38 -
Revenue, 9M: KRW 447.3 billion: 9M 2026, Separate, DART; 누계실적 447,287 - - - 381,996 17.09 -
Revenue, 9M 2025: KRW 382 billion: 9M 2025, Separate, DART; 누계실적 447,287 - - - 381,996 17.09 -
Operating profit, 9M: KRW 56.1 billion: 9M 2026, Separate, DART; 누계실적 56,108 - - - 42,367 32.43 -
Operating profit, 9M 2025: KRW 42.4 billion: 9M 2025, Separate, DART; 누계실적 56,108 - - - 42,367 32.43 -
Operating profit YoY: 48.38%: Q3 2026, Separate, DART; 영업이익 당해실적 23,901 19,306 23.80 - 16,108 48.38 -
Preliminary figures: The figures are preliminary, not final, and may change depending on the closing results.: Q3 2026, DART; ※ 당해 정보는 확정치가 아닌 잠정치로 결산 결과 등에 따라 변경될 수 있음.
Basis of preparation: The results are based on separate financial statements prepared under K-IFRS.: Q3 2026, Separate, DART; 상기 실적은 한국채택국제회계기준(K-IFRS)에 따라 작성된 개별재무제표 기준 영업(잠정) 실적입니다.
Unaudited: The results are internal figures before the external audit is completed and may change with audit results.: Q3 2026, DART; 상기 실적은 외부감사인의 회계감사가 완료되기 이전의 내부결산 자료로 감사결과에 따라 변경될 수 있습니다.

Questions and answers

What was Celltrion Pharm's operating profit in Q3 2026?: KRW 23.9 billion on a separate basis. The comparison figure was KRW 16.1 billion in Q3 2025 (up 48.4%).
What was Celltrion Pharm's revenue in Q3 2026?: KRW 161.9 billion on a separate basis. The comparison figure was KRW 138.2 billion in Q3 2025 (up 17.2%).
What was Celltrion Pharm's net income in Q3 2026?: KRW 17.7 billion on a separate basis. The comparison figure was KRW 11.5 billion in Q3 2025 (up 54.2%).
What should readers check next on Celltrion Pharm?: Check whether the final earnings filing changes the preliminary figures. Check the audit report for any changes after the external audit. Check the quarterly report for how consolidated results differ from separate results.
Which filings is this based on?: 영업(잠정)실적(공정공시) (DART, 2026-11-09).
Is this a buy recommendation?: No. This is for information only and is not investment advice. You are responsible for your own investment decisions and their results.

Key terms

Provisional results: Figures a company releases before its audit or review is finished. They can change in the final filing.
Consolidated basis: Figures that combine a parent company and its subsidiaries as if they were one company.
Separate basis: Figures for the company alone, leaving out its subsidiaries.
Operating profit: Revenue minus the cost of sales and selling and administrative expenses. It shows what the core business earned.
Fair disclosure: A Korean filing that gives material information to everyone at the same time rather than to selected people.

Corrections

No corrections.